Products - Arthritis | Topic | NICE

Showing 6 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Bimekizumab for treating ankylosing spondylitis [TSID10334]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deucravacitinib for treating active psoriatic arthritis [TSID11981]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Filgotinib for Axial spondyloarthritis [ID6594]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tildrakizumab for treating active psoriatic arthritis [TSID12218]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC